LANTHEUS HOLDINGS INC

Curium’s $8 billion all‑cash takeover of Lantheus Holdings could pay shareholders up to $114.50 per share, blending diagnostic expertise with therapeutic assets to create a global radiopharmaceutical leader.

Explore how Lantheus Holdings’ merger with Curium could reshape diagnostic imaging, diversify revenue, boost shareholder value, and drive growth in the healthcare sector.

How Lantheus’s SPECT sale to Shine reshapes the $19 bn nuclear medicine market, boosts Shine’s cardiac imaging reach, and signals a broader med‑tech focus shift.

Discover how Lantheus Holdings’ diagnostic imaging innovations drive global healthcare forward—analyzing its market impact, stock trends, and future growth.

Lantheus Holdings Inc. is facing a wave of class-action lawsuits alleging securities-fraud violations, prompting investors to reassess their positions and potentially leading to financial penalties and reputational damage for the health-care equipme…

Lantheus Holdings Inc has made significant advancements in diagnostic medical imaging, with the FDA reviewing and accepting its new imaging agents, positioning the company for potential growth and expansion in the healthcare sector.

Lantheus Holdings Inc. has sold its SPECT business to SHINE Technologies, allowing the company to focus on its core strengths in radiopharmaceuticals and potentially leading to innovative advancements in diagnostic imaging.

Lantheus Holdings Inc. has achieved a major milestone in Alzheimer’s imaging with its Alzheimer’s Disease Radiodiagnostic agent, MK-6240, successfully meeting co-primary endpoints in pivotal studies.

Lantheus Holdings Inc. is a leading player in the healthcare equipment and supplies sector, specializing in diagnostic medical imaging agents and poised for continued growth and innovation.